


BEST AVAILABLE COPY

Sheet 1 of 9

1/9

Figure 1

Abuse Deterrence Study A8934
(Wt. % ratios SAJB/EL/IPM/CAB 381-20)




- 256-62-02 (71/26/0/3)
- 256-62-04 (66/31/0/3)
- 256-62-06 (70/26/0/4)
- 256-62-08 (65/31/0/4)
- 256-62-10 (68/26/3/3)
- 256-62-12 (63/31/3/3)
- 256-62-14 (67/26/3/4)
- 256-62-16 (62/31/3/4)
- 256-62-21,22,23(66.5/28/5/1.5/3.5)

2/9

BEST AVAILABLE COPY

Figure 2

Abuse Deterrance Study A8965
 (CAB is CAB 381-20 unless otherwise noted)




BEST AVAILABLE COPY

3/9

Figure 3

Abuse Deterrence Study A8983



X03514: SAIB/EL/IM/CAB 381-20 (65/27/3.5/4.5)

X03515: SAIB/EL/IM/CAB 381-20 (65/27/3/5)

X03516: SAIB/EL/IM/CAB 381-20 (63/29/3/5)


X03517: SAIB/EL/IM/CAB 381-20 (63/29/3.5/4.5)

(all contained 12 mg/ml Oxycodone base)

4/9

Figure 4

Abuse Deterrence Study



- X03511 = 59.3; 31.4; 1; 8.6 SAIB; EL; IM; CAB-381-20BP 9mg/g OC


- X03512 = 59.8; 31.4; 1; 7.8 SAIB; EL; IM; CAB-381-20BP 9mg/g OC

- X03713 = 71; 23; 1; 5 SAIB; EL; IM; CAB-381-20BP 9mg/g OC

5/9


Figure 5

Dog Plasma pK Study




6/9

Figure 6



7/9

Figure 7
Drug Dissolution Study



BEST AVAILABLE COPY

8/9

Figure. 8




Figure. 9



Figure. 10



9/9

Figure. 11

